This week’s Industry Watch covers a recently published literature review which sheds much needed light on ‘Long COVID’ and suggests a multifaceted and interdisciplinary approach to care. Also in COVID-19 news, we look at a new smartphone sensor technology which may be used to detect particles of the virus; as well as looking at 3 FDA-approved drugs which show promise in being repurposed to treat COVID-19. There’s also the latest research in diabetes, eczema, endometriosis, and CRISPR.
'Long COVID' - New Review Adds Fresh Detail
In a new literature review, researchers provide a thorough overview of post-acute COVID-19 syndrome, otherwise known as long COVID. The review, which appears in the journal Nature Medicine, highlights the importance of patient advocacy groups and the need for interdisciplinary care and support over a more extended period.
Researchers Look to Use COVID-19-Detecting Sensors in Phones
Researchers at General Electric are set to begin research into how they can turn commonly-used surfaces into COVID-19-detecting devices, the company announced this week.The GE Research team has received a 24-month grant from the National Institutes of Health to develop miniature sensors that can be embedded into mobile devices in order to detect COVID-19 particles on their surfaces.
Three FDA-Approved Drugs that Combat COVID-19 in Lung Cells
Ever since the COVID-19 pandemic was declared over a year ago, researchers around the world have been searching for existing drugs that might be repurposed to fight the virus. A team led by the University of Pennsylvania is adding three candidates to the growing list of potential anti-COVID-19 candidates—medicines they believe are particularly promising because they appear to inhibit the virus in respiratory cells.
Endometriosis: Patient Impact and Why it is so Hard to Diagnose
According to existing data, at least one in every 10 women live with endometriosis. Although this condition can have a serious impact on the quality of life, it often takes women years to have it diagnosed. Medical News Today speak to women living with this condition to find out more about their long journey to a diagnosis.
An Itching Question
Eczema, or atopic dermatitis (AD), is sometimes called “the itch that rashes.” Often, the itch begins before the rash appears, and, in many cases, the itchiness never really goes away. Approximately 9.6 million children and 16.5 million adults in the U.S. have AD, and it can have a serious effect on a person’s quality of life. Although much has been learned about the uncomfortable sensation that triggers the desire to scratch, many mysteries remain about chronic itch, and treatment for the condition remains a challenge.
Stem Cells Show Promise for Non-Healing Diabetic Ulcers in Early Study
Results of a phase 1 study funded by the Diabetes Research Institute Foundation suggest stem cell therapy could be an effective treatment for nonhealing diabetic foot ulcers and possibly reduce the need for amputations in these patients.
Scientists Develop CRISPRoff for Controlling Gene Expression through Heritable Epigenetic Memory
Scientists led by a team at the Whitehead Institute have developed a new gene editing technology, called CRISPRoff, which can be used to control gene expression with high specificity, while leaving the sequence of the DNA unchanged. Utilizing a programmable, epigenetic memory writer protein to silence gene expression, CRISPRoff is a highly specific method that effectively programs epigenetic memory that is heritable for hundreds of cell divisions.